US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by a US government agency.
US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.
